The Minimal Residual Disease Market is expected to witness a staggering CAGR going forward. The gamut of care is being driven by the usage of sensors, digital technologies, and wearables, thereby allowing the healthcare personnel to delve deep into the patients’ live – be it pre-operative, post-operative, or the period in between. Consumer tech companies are into making caregivers visible outside of the clinical environment a reality.
The minimal residual diseases are leukemic cells that stay in a patient during or after treatment. The ongoing treatment of cancer through chemotherapy or radiotherapy is not every time capable of eliminating all the carcinogenic cells and it may moreover be a cause of malignancy.Minimal residual disease test is useful to confirm the traces of leukemic cells during and after the treatment of cancer. The different treatments employed throughout the onset can be tested by minimal residual disease confirmatory test to check the efficacy of the different tests and choose the best treatment to eradicate the cancer cells. The recurrence of cancer and cell proliferation can be quantitatively measured by the minimal residual disease test.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/30403
US FDA approved first Next-Generation Sequencing based test; clonoSEQ Assay that uses multiplex polymerase chain reaction and NGS to identify and quantify certain gene sequences extracted from bone marrow of patients suffering from acute lymphoblastic leukemia and myeloma.
The rising number of patients with cancer is expected to be the prime factor for the growth of minimal residual disease market. The awareness among people to confirm the presence of carcinogens is expected to be the one of the surging drivers for the minimal residual disease market.The patients with ongoing cancer treatment is anticipated to be the most important factor that will grow the minimal residual disease market. The inability of flow cytometry, FISH and polymerase chain reactions to quantify beyond 1 per 100,000 cells is certainly expected to shift the focus of patients towards minimal residual disease market with novel technologies that detect approximately 10 times more for recurrence.
The organ transplants wherein major histocompatibility test is required can be one of the applications where minimal residual disease tests employed for more specificity. The highly funded oncology testing market is expected to rise the number of technologies and the specificity of each test which will help grow the minimal residual disease market.
Get A Customized Scope To Match Your Need Ask An Expert – sales@persistencemarketresearch.com
Minimal Residual Disease Market: Segmentation
| Based on test technique |
|
| Based on detection target |
- Leukemia
- Lymphoma
- Solid Tumors
- Other
|
| Based on test type |
- DNA-based test
- RNA-based test
- Immunological test
|
| Based on end user |
- Hospitals
- Laboratory centers
- Specialty Clinics
|
The minimal residual disease market is broadly classified into FISH, PCR and NGS depending on the test carried out for the detection of the minimal residual disease. Based on the test type the minimal residual disease market is segmented into DNA based test, RNA based test and immunological test.Access Full Report@ https://www.persistencemarketresearch.com/checkout/30403
The segmentation of minimal residual disease market based on the detection target is solid tumors, lymphoma, leukemia and others. The end users of the minimal residual disease market can be hospitals, laboratory centers and specialty clinics.
North America is one of the most prevalent regions in the world for minimal residual disease market, followed by Europe. However, rise in medical tourism in regions such as Brazil, Thailand, Malaysia and Singapore also offer lucrative opportunity for the growth of the minimal residual disease market.Rising number of hospitals in developing regions such as Asia pacific is expected to offer significant growth opportunity for the minimal residual disease market.
Some of the key players operating in the global minimal residual disease market are Adaptive Biotechnologies, Proteus Digital Health, Juno Therapeutics, Navidea Biopharmaceuticals, Kite Pharma, iRepertoire, Inc, Macrogen Corp, Natera, Inc., Macrogen Corp and others.About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com